- Home
- CODA vs HOWL Comparison
CODA vs HOWL Comparison
Compare CODA & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODA | HOWL |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.7M | 48.1M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CODA | HOWL |
|---|---|---|
| Price | $10.93 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 97.7K | ★ 11.3M |
| Earning Date | 06-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.62 | ★ 18.40 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $20,316,161.00 | N/A |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $29.94 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $7.80 | $0.27 |
| 52 Week High | $18.00 | $2.23 |
Technical Indicators
Market Signals| Indicator | CODA | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 64.16 | 68.05 |
| Support Level | $10.85 | $0.56 |
| Resistance Level | $12.24 | $1.14 |
| Average True Range (ATR) | 0.38 | 0.05 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 76.62 | 78.58 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.